Influence of different haemodialysis modalities on AGE peptide levels: intradialytic versus long-term results

Anne van Tellingen, Casper G Schalkwijk, Tom Teerlink, Rob Barto, Muriel P C Grooteman, Tjeerd van der Ploeg, Piet M ter Wee, Menso J Nubé

Research output: Contribution to journalArticleAcademicpeer-review

Abstract

BACKGROUND: Peptide-linked degradation products of advanced glycation end products (AGE peptides) accumulate in chronic haemodialysis (HD) patients and may contribute to a number of HD-related long-term complications, such as accelerated atherosclerosis.

METHODS: The influence of a single HD session versus long-term HD on serum AGE peptides was determined. The patients were randomized to HD with a low-flux polysulfone (PS; F 6HPS), a high-flux PS (F 60S), a superflux PS (F 500S), or a superflux cellulose triacetate (CTA; Tricea 150G) dialyzer.

RESULTS: During a single HD session, both AGE peptides and reference peptides decreased significantly (AGE peptides: Tricea 150G -37.0 +/- 2.9%; F 6HPS -35.5 +/- 2.4%; F 60S -39.5 +/- 4.7%, and F 500S -43.3 +/- 2.1%, p = 0.005; reference peptides: Tricea 150G -73.2 +/- 8.8%; F 6HPS -73.2 +/- 7.9%; F 60S -72.5 +/- 8.2%, and F 500S -74.1 +/- 7.3%, p = 0.005). After 12 weeks of HD with the superflux CTA, the AGE peptide levels decreased significantly (week 1: 2.7 +/- 1.1 arbitrary units, week 12: 2.5 +/- 1.2 arbitrary units, decrease 7.4%; p = 0.01), whereas the AGE peptide levels remained unchanged after HD with each of the other three modalities. The reference peptide levels did not change after 12 weeks of HD.

CONCLUSION: Although AGE peptides can be effectively removed during a single HD session, superflux CTA seems to be the only modality capable of reducing AGE peptides in the long term.

Original languageEnglish
Pages (from-to)c1-c7
JournalNephron. Clinical practice
Volume100
Issue number1
DOIs
Publication statusPublished - 2005

Cite this